share_log

Transcode Therapeutics | ARS: Annual Report to Security Holders

SEC announcement ·  Apr 29 16:05
Summary by Moomoo AI
Transcode Therapeutics, Inc., a Boston-based biotech company specializing in RNA oncology, has completed its annual financial report for the fiscal year ending December 31, 2023. The report, filed with the SEC, reveals that the company's common stock, RNAZ, is listed on The Nasdaq Stock Market LLC. Despite not being a well-known seasoned issuer, Transcode Therapeutics has complied with all SEC filing requirements over the past 90 days and has submitted the necessary Interactive Data Files. As of June 30, 2023, the market value of common stock held by non-affiliates was valued at approximately $4.4 million, with 5,808,053 shares outstanding as of March 20, 2024. The company has announced a strategic collaboration with MD Anderson Cancer Center, committing up to $10 million over five years. Transcode's...Show More
Transcode Therapeutics, Inc., a Boston-based biotech company specializing in RNA oncology, has completed its annual financial report for the fiscal year ending December 31, 2023. The report, filed with the SEC, reveals that the company's common stock, RNAZ, is listed on The Nasdaq Stock Market LLC. Despite not being a well-known seasoned issuer, Transcode Therapeutics has complied with all SEC filing requirements over the past 90 days and has submitted the necessary Interactive Data Files. As of June 30, 2023, the market value of common stock held by non-affiliates was valued at approximately $4.4 million, with 5,808,053 shares outstanding as of March 20, 2024. The company has announced a strategic collaboration with MD Anderson Cancer Center, committing up to $10 million over five years. Transcode's proprietary TTX platform supports a pipeline of RNA therapeutics, including their lead candidate TTX-MC138, which is in early clinical development. Despite receiving FDA authorization for a Phase 0 clinical trial of TTX-MC138, the company faces challenges with Nasdaq's stockholders' equity and minimum bid price requirements, and its financial statements include a going concern note. The annual report also contains forward-looking statements protected by safe harbor provisions.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more